Systematic review finds promising but moderate evidence for **semaglutide** and **tirzepatide** in **T1D** and **LADA**
Background
Patients with autoimmune diabetes, often classified as Type 1 Diabetes (T1D), exhibit significant pathological heterogeneity; up to half may have Latent Autoimmune Diabetes in Adults (LADA), characterized by a slower onset of beta-cell destruction. Current standard-of-care primarily focuses on insulin replacement. However, the potential for residual beta-cell function in some patients, particularly those with LADA, suggests that therapies targeting incretin pathways could offer additional benefits beyond traditional glycemic control, addressing a gap in comprehensive management.
Study Design
A systematic review, adhering to PRISMA guidelines, was conducted to evaluate existing literature on semaglutide or tirzepatide use in adults with T1D or LADA. Researchers searched Ovid MEDLINE, Cochrane CENTRAL, Embase, CINAHL, Web of Science, and ClinicalTrials.gov for studies published between January 1, 2020, and June 12, 2025. The primary objective was to synthesize knowledge regarding the therapeutic application of these second-generation incretin analogs in the specified patient populations, including their potential benefits and challenges.
Results
From 3,053 initial records screened, 11 eligible publications were ultimately selected for analysis. These included two systematic reviews, one post hoc subgroup analysis, six narrative/consensus reviews, and two LADA case reports. The synthesis of these studies revealed three overarching themes: (1) significant inconsistency and frequent diagnostic delays or misdiagnosis of LADA; (2) the identification of potential benefits of tirzepatide and semaglutide for LADA and certain subtypes of T1D; and (3) a review of existing approaches for clinical management in these complex patient groups. The evidence, while promising, was noted to be of moderate quality.
Well-designed, adequately powered randomized trials in clearly defined LADA and T1D populations are needed to clarify long-term efficacy.
Key Findings
- 3,053 records screened yielded 11 eligible publications on semaglutide or tirzepatide in T1D or LADA.
- Eligible studies included two systematic reviews, one post hoc analysis, six narrative reviews, and two LADA case reports.
- Significant inconsistency and diagnostic delays were identified for Latent Autoimmune Diabetes in Adults (LADA).
- Potential benefits of tirzepatide and semaglutide were noted for LADA and certain T1D types.
- Well-designed, adequately powered randomized trials are needed to clarify long-term efficacy.
Why It Matters
This review highlights that semaglutide and tirzepatide may offer multiple benefits for adults with autoimmune diabetes who retain residual beta-cell function, particularly those with LADA. For clinicians and biohackers, this suggests a potential adjunctive therapy to insulin, moving beyond traditional glycemic control to possibly preserve beta-cell mass or improve metabolic health in these specific populations. However, the current evidence is of moderate quality, meaning clinical translation requires caution and further robust research. The findings underscore the critical need for improved diagnostic accuracy for LADA to identify patients most likely to benefit from these incretin analogs, as current management is challenging due to diagnostic inconsistencies.
semaglutide
tirzepatide
type-1-diabetes
lada
autoimmune-diabetes
systematic-review